One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for MOG Antibody-Associated Disease. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
The FDA is expected to decide on Enspryng for MOG antibody-associated disease (MOGAD) by January 10, 2027, under an sBLA from Genentech (Roche).
What the FDA is deciding on Enspryng for MOG antibody-associated disease
The FDA is reviewing Genentech (Roche)'s request to approve Enspryng (satralizumab) for a new use, MOG antibody-associated disease (MOGAD).
Priority review. Would be the first approved treatment for MOGAD, a rare autoimmune disease that attacks the optic nerves, spinal cord and brain. In the Phase 3 METEOROID trial, Enspryng cut the risk of relapse by 68%, with 87% of treated patients relapse-free at 48 weeks versus 67% on placebo. Already approved for NMOSD and, since October 2026, thyroid eye disease.
Who the Enspryng decision matters to
MOG antibody-associated disease (MOGAD) is a rare autoimmune condition in which antibodies attack a protein on the myelin coating of nerves in the optic nerves, spinal cord and brain, causing attacks of vision loss, weakness, numbness and, in children, brain inflammation. A reliable antibody test, available since 2017, now separates it from multiple sclerosis and NMOSD. No drug is approved for it.
Enspryng (satralizumab), already approved for NMOSD, has an FDA decision for MOGAD due January 10, 2027.
Prevalence: Roughly 0.5 to 3.4 people per 100,000 (Genentech); the MOG antibody is found in 40-58% of children with ADEM and in 7.4-39% of people with NMOSD who test negative for the aquaporin-4 antibody. See our full MOG Antibody-Associated Disease page for current treatments, recruiting trials, and community resources.
How Enspryng works
Enspryng: humanized recycling antibody against the interleukin-6 receptor, binding both the soluble and membrane-bound forms to block IL-6 signaling. Our full Enspryng profile covers how it works, side effects in plain language, and its trial history.
What an approval or a rejection of Enspryng would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.
Where MOG Antibody-Associated Disease treatment stands today
Read our full MOG Antibody-Associated Disease treatment summary
There is no FDA-approved treatment for MOGAD as of October 2026, and the first could arrive in January. Enspryng (satralizumab), Genentech's monthly under-the-skin injection that blocks the interleukin-6 receptor, is approved for aquaporin-4 NMOSD and was tested in MOGAD in the Phase 3 METEOROID trial (NCT05271409) in adults and adolescents 12 and older, who could stay on their existing preventive medicine during the study.
Enspryng cut the risk of a new relapse by 68% compared with placebo, with 87% of patients relapse-free at 48 weeks versus 67% on placebo, and it reduced active lesions on MRI by 79% and the need for rescue treatment by 73%. The most common side effects were injection reactions, flu, joint pain and back pain.
Genentech announced on September 9, 2026 that the FDA had granted priority review, with a decision expected by January 10, 2027; a European decision is expected in the third quarter of 2027. The same drug was approved for thyroid eye disease in October 2026.
A second drug, rozanolixizumab from UCB, works differently, by blocking the FcRn receptor so the body clears antibodies faster, and is being tested as a weekly injection in the Phase 3 cosMOG trial (NCT05063162). That trial has finished enrolling, and UCB expects results in the second half of 2027.
Academic studies are also comparing immediate against delayed azathioprine or rituximab after a first attack, and testing tocilizumab, an older IL-6 blocker. In a 2026 JAMA Neurology study that looked back at records of 116 people with MOGAD given an IL-6 blocker, mostly tocilizumab, the yearly relapse rate in those with relapsing disease fell from 0.64 before treatment to 0.09 during it.
A neurologist who specializes in neuroimmunology is the right person to ask about trials, and the MOG Project, the Siegel Rare Neuroimmune Association and the Sumaira Foundation all run support programs for MOGAD specifically, and the MOG Project and the Sumaira Foundation publish plain-language trial guides.
The MOG Antibody-Associated Disease page has every treatment and trial →Meanwhile, 18 MOG Antibody-Associated Disease studies are recruiting or not yet recruiting
Whatever the FDA decides here, research on MOG Antibody-Associated Disease does not stop. Of these, 9 test a treatment; the others follow patients over time. The most recently updated:
We'll email you when the decision is public, with what it means in plain language, and when new trials open for MOG Antibody-Associated Disease. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
One email the day each decision on our calendar is announced, for any condition. No trial alerts and no condition to pick.
We never share your email. Stop anytime from the link in every email. Privacy policy
Frequently asked questions
When will the FDA decide on Enspryng?
The FDA's target date (PDUFA date) for Enspryng in MOG antibody-associated disease (MOGAD) is January 10, 2027.
Who disclosed it: Genentech (Roche). The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
Source: Genentech press release
What is Enspryng being reviewed for?
Genentech (Roche) submitted an sBLA for Enspryng in MOG antibody-associated disease (MOGAD).
What to know: Priority review. Would be the first approved treatment for MOGAD, a rare autoimmune disease that attacks the optic nerves, spinal cord and brain. In the Phase 3 METEOROID trial, Enspryng cut the risk of relapse by 68%, with 87% of treated patients relapse-free at 48 weeks versus 67% on placebo. Already approved for NMOSD and, since October 2026, thyroid eye disease.
How it works: Humanized recycling antibody against the interleukin-6 receptor, binding both the soluble and membrane-bound forms to block IL-6 signaling.
More: the Enspryng drug page explains it in plain language.
Is there already an FDA-approved treatment for MOG Antibody-Associated Disease?
No. No medicine's current FDA label names MOG Antibody-Associated Disease, checked October 21, 2026.
Check: the MOG Antibody-Associated Disease page also searches FDA drug labels for approved treatments.
What did the Enspryng trials show?
For MOG antibody-associated disease, the Phase 3 METEOROID trial cut the risk of relapse by 68%, with 87% of treated patients relapse-free at 48 weeks against 67% on placebo.
More: the Enspryng drug page has the full trial history and sources.
What are the side effects of Enspryng?
The label carries no boxed warning. Its warnings are the ones shared by IL-6 receptor blockers: an increased risk of infections including serious and potentially fatal ones, raised liver enzymes, lowered neutrophil counts and hypersensitivity reactions.
Most common: Nasopharyngitis, Headache, Upper respiratory infection, Gastritis, Rash, Joint and limb pain.
More: the Enspryng drug page has the label's warnings in full.
Can I get Enspryng before the FDA decides?
Enspryng is already FDA approved for other conditions, but not yet for MOG antibody-associated disease (MOGAD), and insurers may not cover use for an unapproved condition.
Trials: 18 MOG Antibody-Associated Disease studies are recruiting or not yet recruiting, 9 of them testing a treatment. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask Genentech (Roche) directly. Registered programs are listed on ClinicalTrials.gov.
How much will Enspryng cost?
Enspryng is already sold in the US for other conditions. Trial Friend does not list a price, and coverage for MOG antibody-associated disease (MOGAD) depends on the FDA decision and your insurer.
Drugmaker help: Genentech Access Solutions for Enspryng.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Enspryng decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Genentech press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.